Clinical Trials

Verified stories whose regulatory record supports clinical-trial access. Eligibility and enrollment are never guaranteed.

Filter clinical trials

Results

97 verified trial-access stories match your filters.

Important: Eligibility and enrollment are not guaranteed, and listing here is not a treatment recommendation. Talk to your care team.

Trial Watch: A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer

InvestigationalLater-Stage Human

Cancer type: Lung Cancer
Trial identifier: NCT06497556
Trial phase: Phase 3

View trial details

Study design: Other / not applicable
Population: Participants age 18 Years and older with Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer who meet the study-specific registry eligibility criteria.
Last reviewed: 2026-09-16

Regulatory status by jurisdiction

Unspecified jurisdiction

Status: Investigational
Last verified: 2026-09-16

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Primary evidence supporting this story

ClinicalTrials.gov — NCT06497556 (opens in a new tab) (Clinical-trial registry) NCT06497556 Load-bearing source NCT06497556
ClinicalTrials.gov — NCT06497556. NCT06497556.

Eligibility varies — review trial criteria.

Trial Watch: Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

InvestigationalLater-Stage Human

Cancer type: Bladder Cancer
Trial identifier: NCT05987241
Trial phase: Phase 3

View trial details

Study design: Other / not applicable
Population: Participants age 18 Years and older with Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma, Muscle Invasive Ureter Urothelial Carcinoma, Muscle Invasive Urethral Urothelial Carcinoma who meet the study-specific registry eligibility criteria.
Last reviewed: 2026-09-16

Regulatory status by jurisdiction

Unspecified jurisdiction

Status: Investigational
Last verified: 2026-09-16

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Primary evidence supporting this story

ClinicalTrials.gov — NCT05987241 (opens in a new tab) (Clinical-trial registry) NCT05987241 Load-bearing source NCT05987241
ClinicalTrials.gov — NCT05987241. NCT05987241.

Eligibility varies — review trial criteria.

Trial Watch: A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Lymphoblastic Leukaemia

InvestigationalLater-Stage Human

Cancer type: Leukemia
Trial identifier: NCT07223190
Trial phase: Phase 3

View trial details

Study design: Other / not applicable
Population: Participants ages 18 Years to 100 Years with Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukemia who meet the study-specific registry eligibility criteria.
Last reviewed: 2026-09-16

Regulatory status by jurisdiction

Unspecified jurisdiction

Status: Investigational
Last verified: 2026-09-16

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Primary evidence supporting this story

ClinicalTrials.gov — NCT07223190 (opens in a new tab) (Clinical-trial registry) NCT07223190 Load-bearing source NCT07223190
ClinicalTrials.gov — NCT07223190. NCT07223190.

Eligibility varies — review trial criteria.

Trial Watch: A Phase III Study to Evaluate the Efficacy and Safety of JYP0322 in Previously Untreated ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer

InvestigationalLater-Stage Human

Cancer type: Lung Cancer
Trial identifier: NCT07816380
Trial phase: Phase 3

View trial details

Study design: Other / not applicable
Population: Participants age 18 Years and older with NSCLC (Advanced Non-small Cell Lung Cancer) who meet the study-specific registry eligibility criteria.
Last reviewed: 2026-09-15

Regulatory status by jurisdiction

Unspecified jurisdiction

Status: Investigational
Last verified: 2026-09-15

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Primary evidence supporting this story

ClinicalTrials.gov — NCT07816380 (opens in a new tab) (Clinical-trial registry) NCT07816380 Load-bearing source NCT07816380
ClinicalTrials.gov — NCT07816380. NCT07816380.

Eligibility varies — review trial criteria.

Trial Watch: A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer

InvestigationalLater-Stage Human

Cancer type: Stomach (Gastric) Cancer
Trial identifier: NCT06901531
Trial phase: Phase 3

View trial details

Study design: Other / not applicable
Population: Participants age 18 Years and older with Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma who meet the study-specific registry eligibility criteria.
Last reviewed: 2026-09-15

Regulatory status by jurisdiction

Unspecified jurisdiction

Status: Investigational
Last verified: 2026-09-15

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Primary evidence supporting this story

ClinicalTrials.gov — NCT06901531 (opens in a new tab) (Clinical-trial registry) NCT06901531 Load-bearing source NCT06901531
ClinicalTrials.gov — NCT06901531. NCT06901531.

Eligibility varies — review trial criteria.

Trial Watch: Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.

InvestigationalLater-Stage Human

Cancer type: Stomach (Gastric) Cancer
Trial identifier: NCT07217704
Trial phase: Phase 3

View trial details

Study design: Other / not applicable
Population: Participants age 18 Years and older with Esophageal Cancer, Gastric Cancer (GC), Gastroesophageal Junction who meet the study-specific registry eligibility criteria.
Last reviewed: 2026-09-15

Regulatory status by jurisdiction

Unspecified jurisdiction

Status: Investigational
Last verified: 2026-09-15

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Primary evidence supporting this story

ClinicalTrials.gov — NCT07217704 (opens in a new tab) (Clinical-trial registry) NCT07217704 Load-bearing source NCT07217704
ClinicalTrials.gov — NCT07217704. NCT07217704.

Eligibility varies — review trial criteria.

Trial Watch: Intravesical BCG vs GEMDOCE in NMIBC

InvestigationalLater-Stage Human

Cancer type: Bladder Cancer
Trial identifier: NCT05538663
Trial phase: Phase 3

View trial details

Study design: Other / not applicable
Population: Participants age 18 Years and older with Non-muscle-invasive Bladder Cancer who meet the study-specific registry eligibility criteria.
Last reviewed: 2026-09-15

Regulatory status by jurisdiction

Unspecified jurisdiction

Status: Investigational
Last verified: 2026-09-15

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Primary evidence supporting this story

ClinicalTrials.gov — NCT05538663 (opens in a new tab) (Clinical-trial registry) NCT05538663 Load-bearing source NCT05538663
ClinicalTrials.gov — NCT05538663. NCT05538663.

Eligibility varies — review trial criteria.

Trial Watch: A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

InvestigationalLater-Stage Human

Cancer type: Breast Cancer
Trial identifier: NCT06065748
Trial phase: Phase 3

View trial details

Study design: Other / not applicable
Population: Participants age 18 Years and older with Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer who meet the study-specific registry eligibility criteria.
Last reviewed: 2026-09-14

Regulatory status by jurisdiction

Unspecified jurisdiction

Status: Investigational
Last verified: 2026-09-14

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Primary evidence supporting this story

ClinicalTrials.gov — NCT06065748 (opens in a new tab) (Clinical-trial registry) NCT06065748 Load-bearing source NCT06065748
ClinicalTrials.gov — NCT06065748. NCT06065748.

Eligibility varies — review trial criteria.

Trial Watch: Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)

InvestigationalLater-Stage Human

Cancer type: Bladder Cancer
Trial identifier: NCT07566156
Trial phase: Phase 3

View trial details

Study design: Other / not applicable
Population: Participants age 18 Years and older with Urothelial Cancer, Urinary Bladder Neoplasms who meet the study-specific registry eligibility criteria.
Last reviewed: 2026-09-11

Regulatory status by jurisdiction

Unspecified jurisdiction

Status: Investigational
Last verified: 2026-09-11

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Primary evidence supporting this story

ClinicalTrials.gov — NCT07566156 (opens in a new tab) (Clinical-trial registry) NCT07566156 Load-bearing source NCT07566156
ClinicalTrials.gov — NCT07566156. NCT07566156.

Eligibility varies — review trial criteria.

Trial Watch: Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

InvestigationalLater-Stage Human

Cancer type: Breast Cancer
Trial identifier: NCT06393374
Trial phase: Phase 3

View trial details

Study design: Other / not applicable
Population: Participants age 18 Years and older with Triple-Negative Breast Cancer who meet the study-specific registry eligibility criteria.
Last reviewed: 2026-09-11

Regulatory status by jurisdiction

Unspecified jurisdiction

Status: Investigational
Last verified: 2026-09-11

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Primary evidence supporting this story

ClinicalTrials.gov — NCT06393374 (opens in a new tab) (Clinical-trial registry) NCT06393374 Load-bearing source NCT06393374
ClinicalTrials.gov — NCT06393374. NCT06393374.

Eligibility varies — review trial criteria.

CancerDiscoveries summarizes verified records in its database. Absence of a listing here does not establish that a treatment lacks regulatory authorization or access.